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Summary Background. It is unclear whether the respiratory tract is involved in eliciting or
aggravating eczematous lesions in patients with vesicular hand eczema.
Objectives. To investigate the effect of inhalation of house dust mite (HDM) on
vesicular hand eczema.
Methods. Eighteen patients with vesicular hand eczema and HDM allergy received
inhalation challenges with four concentrations of HDM in a randomized, double-
blind, placebo-controlled, cross-over study. Early asthmatic reactions and late asthmatic
reactions were defined as a placebo-corrected fall of 15% or more from baseline of forced
expiratory volume in 1 second. Hand eczema was scored according to the Dyshidrotic
Eczema Area and Severity Index (DASI) at baseline, and 1, 6, 24 and 48 hr.
Results. The median DASI increased significantly as compared with baseline at 6
and 48 hr after HDM inhalation. This increase was significantly different between the
provocations at 6 hr. The median vesicles score increased significantly from baseline at
24 and 48 hr. Patients with a placebo-corrected increase in the number of vesicles at 24
hr and 48 hr had significantly more often late asthmatic reactions than those without
an increase in the number of vesicles. Patients with a placebo-corrected increase of the
DASI score at 24 hours had as a group a higher mean total IgE level than those without
an increase of the DASI score.
Conclusion. Hand eczema increased significantly more after HDM provocation than
after placebo provocation. An increase in the number of vesicles was preceded by late
asthmatic reactions. The group patients with an increase of hand eczema tended to have
a higher mean total IgE level.
Key words: allergens; bronchial provocation tests; Dermatophagoides pteronysinnus;
dyshidrotic eczema.
Hand eczema is not a homogeneous disease entity.
It is associated with many different aetiologies and
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morphologies. External and predisposing endogenous
factorsplaya role inhandeczema.Beingatopic is assumed
to be related to the risk of developing and maintaining
hand eczema.Vesicular hand eczema (dyshidrotic eczema
or pompholyx) is, by definition, the development of
isolated vesicles on the palms, the palmar aspects of
the fingers, and the sides of the fingers. The condition is
eruptive, and is accompanied by inflammatory erythema
of variable intensity and severe pruritus. The cause may
be exposure to allergens or irritants, or unknown. The
degree of association between vesicular hand eczema
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and atopy is unclear. In 1992, Lodi et al. (1) reported
atopy to be a predisposing factor in the pathogenesis of
vesicular hand eczema. In 2003, Bryld et al. (2) reported
no association of vesicular hand eczema and atopic
dermatitis or atopy, defined as a history or the presence of
asthma, hay fever, flexural eczema, or childhood eczema.
The pathogenic role of house dustmite (HDM) in atopic
dermatitis remainsunclear, andambiguous findingshave
been reported. Studies on HDM in impermeable mattress
casings showed some effect (3, 4) or no effect (5, 6). The
respiratory route may be relevant in the exacerbation
of atopic dermatitis. In 1996, Tupker et al. (7) reported
that inhalation of HDM aggravated dermatitis in patients
with atopic dermatitis who had early asthmatic reactions
(EARs). Brinkmanet al. (8) reported in1997 that allergen
inhalation challenge caused a flare-up of skin lesions
in atopic dermatitis patients, and that it was more
prominent in atopic dermatitis patients who already had
IgE-mediated allergic inflammation in the lung.
On the basis of present knowledge, we assumed that
a significant proportion of patients with vesicular hand
eczema are allergic to HDM. Therefore, we hypothesized
that the respiratory tract could be involved in eliciting or
aggravatingeczematous lesions.Theaimof this studywas
to investigate the effect of inhalation provocation with
HDM on vesicular hand eczema in atopic individuals.
Further insights may be helpful in guiding future




This was a randomized, double-blind, placebo-controlled,
cross-over study.
Setting and study period
The study site was the dermatology outpatient clinic and
thedepartmentofAllergyof theUniversityMedicalCenter
in Groningen, The Netherlands. Data were collected
between 2003 and 2010.
Inclusion and exclusion criteria
Eligible patients were aged 18–70 years with a mor-
phological diagnosis of vesicular hand eczema (9). We
included patients who had mild to moderate vesicular
hand eczema, disease severity of 0–60 according to the
Dyshidrotic Eczema Area and Severity Index (DASI) (10),
and a positive prick test reaction to Dermatophagoides
pteronyssinus (SQ 503, 10 000 BU/ml; ALK Benelux,
Lelystad, The Netherlands). A positive prick test reaction
was defined as a histamine equivalent prick of ≥ 0.5.
Exclusion criteria were severe asthma, a forced
expiratory volume in 1 second (FEV1) < 80% of the
predicted value, and pregnancy. Other exclusion criteria
were phototherapy, systemic corticosteroids, inhaled
corticosteroids, nedocromil, disodium cromoglycate or
other systemic immunomodulating drugs within the past
4 weeks, antihistamines and β-blocking drugs in the
previous7 days, long-actingβ2-sympathomimetics in the
previous 48 hr, and short-acting β2-sympathomimetics
in the previous 12 hr.
Procedure
Patientswhowere referred for vesicular hand eczemaand
who had been treated for vesicular hand eczema in recent
years at the department of Dermatology were asked to
participate. A request for participation in the study was
also made in a local newspaper. Patients were informed
of the study by an independent physician. If they were
interested in participating, they received an appointment
for screening on eligibility by the investigator. The
patients were tested for type 1 allergy by prick testing
with HDM allergen (D. pteronyssinus). Examination for
pulmonary pathology was followed by measurement of
spirometry (vital capacity and FEV1). Fungal infections
on the hands and feet were ruled out. When patients
fulfilled the inclusion criteria, they were included in the
study. A history of asthma was defined as present if
patients reported a diagnosis of asthma by a physician.
A history of atopic dermatitis was defined as present
if patients reported a diagnosis of atopic dermatitis
confirmed by a physician. Current atopic dermatitis was
defined according to the UKworking party criteria (11). If
patients used topical steroids or other anti-inflammatory
topical medications, they had to continue it at the same
frequency and strength during the study.
Randomization and blinding
A laboratory technician not directly involved in the study
used a computer-generated randomization scheme to
determine the sequence of challenges, so that the patients
and the investigators were unaware of the nature of the
challenge. The outcome assessor trained in scoring hand
eczema severity was blinded. The code was broken after
the last challenge had been performed and the response
had been scored.
Ethics committee
The protocol was approved by the local research ethics
committee, and written informed consent was obtained
from all of the participants.
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Inhalation provocation
The active test solution consisted of four concentrations
(80, 400, 2000 and 10 000 BU/ml) of standardized
HDM (D. pteronyssinus, SQ 503; ALK Benelux) diluted
in phosphate buffer containing 0.5% phenol and 0.03%
human serum albumin. The placebo test solution
consisted of the phosphate buffer containing 0.5% phenol
and 0.03% human serum albumin. Challenges always
startedbetween8.30and9.00 in themorning. Increasing
concentrations were inhaled for 1 min at intervals of
15 min. In patients 1–6, spirometry was performed with
a rolling seal dry spirometer (Morgan 130; Morgan Ltd,
Rainham, Gillingham, UK) fitted to a two-way valve box.
This was connected to a De Vilbiss 464 nebulizer (De
Vilbiss Medizinische GmbH, Langen, Germany) with an
output of 0.13 ml/min. Patients 7–18 were tested with
the Masterlab Trans spirometer (Spirometer Erich Jaeger
AG, Wu¨rzburg, Germany). All equipment was calibrated
weekly.
An EAR and a late asthmatic reaction (LAR) may
occur after exposure to an allergen. FEV1 was measured
at different times in order to assess EARs and LARs (12).
FEV1 was measured immediately before and immediately
after each challenge dose. After the last challenge, FEV1
was measured after 15, 20, 30, 40, 50 and 60 min.
Thereafter, FEV1 was measured hourly in a standard
manner from 11.00 to 17.00.
The inhalation was stopped as soon as the fall in FEV1
from baseline was ≥ 15%. In that case, the following
schedule was used: FEV1 was measured after 15, 20,
30, 40, 50 and 60 min. The placebo challenge procedure
was the same as described for the active suspension. The
time interval between HDM and placebo challenges was
2–4 weeks.
If an EAR occurred and the FEV1 decreased from
baseline by > 35%, the patients received two doses of
200 μg of salbutamol by inhalation. In cases of LAR,
the patients were prescribed 200 μg of salbutamol and
400 μg of budesonide. The dose was determined by the
amount of the fall in FEV1.
Assessments
Hand eczema
Hand eczema was scored with the DASI before the
first challenge and 1, 6, 24 and 48 hr after the first
challengeon theHDMdayandontheplaceboprovocation
day (10). This index combines intensity items (vesicles,
erythema, and desquamation) with the subjective item
(itch), and with the extent of the affected area. Vesicles
was scored as the estimation of the total number of
vesicles divided by the total size of the affected area in
square centimetres (0 points, absent; 1 point, >0 to
< 2 vesicles/cm2; 2 points, 2–8 vesicles/cm2; 3 points,
> 8 vesicles/cm2). Erythema, desquamation and itch
were scored from 0 to 3 for each item (0 points, absent;
1 point, mild; 2 points, moderate; 3 points, severe).
Grading of the items erythema, desquamation and itch
was representative for all of theaffectedareas. Theaffected
area was scored on the basis of the mean percentage
of affected skin of the total palm (0 points, absent;
1 point, 1–20%; 2 points, 21–40%; 3 points, 41–60%;
4 points, 61–80%; 5 points, 81–100%). The total score
results from the sum of the four intensity/subjective
items (vesicles, erythema, desquamation, and itch) were
multiplied by the affected area score points to provide
a score ranging from 0 to 60 for one hand. The sum
of the right hand and the left hand provided the DASI
score,which ranged from0 to 120,with the higher scores
representing more severe eczema. The DASI sub-scores
of the items vesicles, erythema, desquamation and itch
were each scored from 0 to 3 points. The sum of the
sub-scores of the right hand and the left hand was the
DASI sub-score, which ranged from 0 to 6 for the items
vesicles, erythema, desquamation and itch, and from 0
to 10 for the sub-score affected area. The assessment of
hand eczema was carried out by one experienced nurse
practitioner.
Spirometry
The fall in the FEV1 values, represented as FEV1,
was expressed as the percentage change from baseline,
which was measured at the start of both provocation
days. The maximum FEV1 values were corrected
for diurnal variation, to produce the FEV1 placebo-
corrected in the first hour after the provocation and
FEV1 placebo-corrected 3–8 hr after the provocation,
according to the following formula: FEV1 placebo-
corrected (% baseline) = maximum FEV1 HDM (%
baseline) – corresponding FEV1 placebo (% baseline).
The EAR was defined as FEV1 placebo-corrected (%
baseline) ≥ 15% in the first hour after the provocation.
The LAR was defined as FEV1 placebo-corrected (%
baseline) ≥ 15% 3–8 hr after the provocation.
Serum IgE levels and eosinophils
Serum eosinophils were measured on both provocation
days before the first challenge and 24 hr after the
first challenge. Serum concentrations of eosinophils
> 0.4 × 109/l were considered to be increased.
We evaluated total IgE levels and HDM (D. pteronyssi-
nus)-specific IgE levelsat thestartof everyfirstprovocation
© 2012 John Wiley & Sons A/S
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day. Serum concentrations of total IgE and HDM-specific
IgE were measured with the Radio Allergosorbent Test.
Total IgE > 115 kU/l and specific IgE HDM > 0.35 kU/l
were considered as positive.
Outcomes
The primary outcome was the between-provocation
(HDM versus placebo) differences in DASI at 48 hr.
The change in DASI scores and DASI sub-scores at the
different time points were corrected for baseline values,
represented as DASI and DASI sub-scores.
Secondary outcome parameters included: between-
provocation comparison of the DASI scores at 1, 6 and
24 hr; between-provocation comparison of the DASI
sub-scores at the different time points; and changes in
DASI scores and DASI sub-scores from baseline after
HDM and placebo provocation.
We defined HDM responders and placebo responders
at different time points as DASI > 0. As there were
patients who responded both to HDM and to placebo,
we found it necessary to correct the eczema response to
HDM for the response to placebo to define skin responders:
DASI after HDM > 0 and DASI after HDM > DASI
after placebo.We defined sub-score responders as follows:
DASI sub-score after HDM > 0 and sub-score after
HDM > sub-score after placebo.
Further secondary outcomes were the differences in:
the number of HDM (sub-score) responders and placebo
(sub-score) responders; EAR and LAR in skin responders
and non-skin responders; EAR and LAR in sub-score
responders and non-sub-score responders; correlations
between the percentage fall in FEV1 and skin responders
and non-skin responders; and serum IgE levels and blood
eosinophils.
Determination of sample size
The sample size was established on the basis of the
presumed difference from baseline of DASI 48 hr after
the inhalation provocation. In this two-period cross-over
study, there are two DASIs per patient. The standard
deviation(SD)of theseDASIs isestimatedtobe28points.
The mean DASI after HDM provocation is compared
with the mean DASI after placebo. We expected the
DASI to increase by 28 points after HDM provocation and
to not increase after placebo provocation. With α = 0.05
and β = 0.2, each group should consist of 18 patients
(two-sided two-sample t-test).
Statistical analysis
Baseline characteristics are presented as follows: mean
(SD)age(years)andn(%)males.Forcontinuousvariables,
the Kolmogorov–Smirnov test was used to compare the
distributionof thepatient scoreswith the standardnormal
distribution. If the scores fitted the normal distribution,
the paired t-test was used for post hoc comparisons. If
scores were not normally distributed, the Wilcoxon test
for non-parametric paired datawas used for comparisons.
Differences in the number ofHDMresponders and placebo
responders were analysed with McNemar’s test.
Differences between EAR in skin responders and non-
skin responders and LAR in skin responders and non-skin
responderswere analysedwith Fisher’s exact test. Logistic
regression analysis was used to investigate associations
between the percentage fall in FEV1 and skin responders
versus non-skin responders.
Comparisons of IgE levels and eosinophils after
HDM provocation in skin responders versus non-skin
responders were analysed with an independent samples
t-test. In theanalysis, a serumconcentrationof total IgEof
> 5000 kU/l was considered as 5000 kU/l, HDM-specific
IgE > 100 kU/l was considered as 100 kU/l, and HDM-
specific IgE < 0.35 kU/l was considered as 0.35 kU/l.
PASW™ statistics 18.0 was used for data analyses.
Results
One hundred and forty-nine patients were approached
to participate at the department of Dermatology.
Recruitment for participation via the newspaper led to
a reaction from 34 individuals who were interested
in participating in the study. The participant flow
throughout the recruitment and inclusion procedure is
shown in Fig. 1. A total of 18 patients were randomized
to determine the sequence of challenges.
The baseline characteristics of the study population
and the baseline serumeosinophils on theHDMchallenge
day and the placebo challenge day are summarized in
Table 1. The mean age was 38 years (SD ± 14 years).
Five (28%) males and 13 (72%) females participated in
the study.
Hand eczema
As shown inTable 2, significant increases inmedianDASI
score and median DASI sub-scores were seen only after
provocation with HDM. After placebo provocation, no
significant differences frombaselinewere seen at any time
point.
At 48 hr, a significant increase in median DASI as
compared with baseline was seen after HDM provocation
(p = 0.005), but no significant difference in DASI
between HDM and placebo was seen at that time point.
A significant increase in median DASI as compared
© 2012 John Wiley & Sons A/S
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Fig. 1. Patient flow throughout the recruitment and inclusion procedure.
Table 1. The baseline characteristics of the study population












1 20 M − − − 109 30 30 − 0.57 212 1.31
2 30 M − + − 83 4 8 0.52 0.50 11.7 < 0.35
3 52 F − + − 121 5 4 0.29 0.27 2517 11.1
4 21 F − + + 106 3 16 0.71 1.13 90.2 5.64
5 43 F − + + 109 43 50 0.73 0.55 1446 4.37
6 25 F + + − 110 5 7 0.29 2.64 55 15.1
7 53 F − + − 112 17 11 0.55 0.57 > 5000 > 100
8 23 M − + − 125 8 7 0.42 0.16 117 20.9
9 60 M − + − 90 16 15 0.48 0.33 52.8 0.45
10 47 F − + + 112 40 40 0.26 0.17 50.6 0.82
11 50 F − + + 100 28 56 0.02 0.06 81.8 0.89
12 43 F − + + 99 4 2 0.12 0.11 9.5 1.90
13 48 F − + + 99 16 30 0.44 0.37 219 29.50
14 26 F + + + 117 0 2 0.80 0.96 407 66.20
15 24 F + + + 106 0 3 0.42 0.36 708 73.70
16 57 M + − − 100 0 1 0.30 0.42 67.1 1.28
17 35 F + − − 92 2 2 0.13 1.43 > 5000 > 100
18 21 F + + − 99 5 2 0.47 0.47 1213 >100
AD, atopic dermatitis; DASI, Dyshidrotic Eczema Area and Severity Index; F, female; FEV1, forced expiratory volume in 1 second represented
as % predicted; HDM, house dust mite; M, male.
FEV1 (% predicted) and serum IgE levels were assessed on the first provocation day before the challenges.
∗Physician diagnosis.
†Current AD according to criteria of the UK working party.
with baseline was noted after HDM provocation at
6 hr (p = 0.045), and, at that time point, DASI was
significantly different between the provocations (HDM
versus placebo) (p = 0.03).
The median vesicles score showed significant
increases from baseline at 24 hr (p = 0.03) and 48 hr
(p = 0.03), but no significant differences in vesicles
between the provocations (HDM versus placebo) were
seen at these time points.
The median erythema score showed no significant
increase from baseline at any time point, but  ery-
thema between the provocations (HDM versus placebo)
© 2012 John Wiley & Sons A/S
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Table 2. Median Dyshidrotic Eczema Area and Severity Index (DASI) scores [interquartile range (IQR)] and DASI sub-scores (IQR)
Baseline 1 hr 6 hr 24 hr 48 hr
House dust mite (n = 18)
DASI 5.0 (2.75–19.75) 5.0 (2.75–20.50) 6.0 (2.75–22.00)
p = 0.045
6.0 (3.00–21.75) 8.5 (4.00–22.50)
p = 0.005




Erythema 1.0 (0.00–2.00) 1.0 (0.00–2.00) 1.0 (0.00–2.00) 1.0 (0.00–2.00) 1.0 (0.00–2.00)
Desquamation 2.0 (0.75–2.25) 2.0 (0.75–2.25) 2.0 (0.75–2.25) 2.0 (0.75–2.25) 2.0 (0.75–3.00)
Itch 2.0 (0.00–2.00) 2.0 (0.00–2.00) 2.0 (0.00–2.00) 2.0 (0.00–2.25) 2.0 (0.00–2.00)
Affected area 2.0 (2.00–4.75) 2.0 (2.00–4.75) 2.0 (2.00–4.75) 2.0 (1.75–4.75) 2.5 (1.75–4.75)
Placebo (n = 18)
DASI 7.5 (2.00–30.00) 7.5 (2.00–31.50) 7.5 (2.00–30.75) 7.5 (2.75–31.50) 7.5 (3.75–30.00)
Vesicles 1.0 (0.00–2.00) 1.0 (0.00–2.00) 1.0 (0.00–2.00) 1.0 (0.00–3.00) 1.5 (0.00–3.00)
Erythema 2.0 (0.00–2.00) 2.0 (0.00–2.00) 2.0 (0.00–2.00) 2.0 (0.00–2.00) 2.0 (0.00–2.00)
Desquamation 2.0 (1.00–2.25) 2.0 (1.00–2.25) 2.0 (1.00–2.25) 2.0 (1.75–3.25) 2.0 (1.75–3.25)
Itch 2.0 (0.00–3.00) 2.0 (0.00–2.25) 2.0 (0.00–2.25) 2.0 (0.00–2.25) 2.0 (0.00–2.00)
Affected area 2.0 (2.00–6.25) 2.0 (2.00–6.25) 2.0 (2.00–6.25) 2.0 (2.00–6.25) 2.0 (2.00–6.25)
p-values are shown only for significant differences from baseline.
was significantly different at 6 hr (p = 0.03) and 24 hr
(p = 0.04).
The median itch score showed no significant increase
from baseline at any time point. We expected that sig-
nificant increases in the median vesicles score at 24 and
48 hr would be accompanied by an increase in itch.
Table 4 shows that 6 patients had an increase in vesicles
from baseline after HDM challenge at 48 hr, represented
as vesicles 48 hr. In 5 of these 6 patients, an increase
in vesicles at 48 hr was accompanied by moderate itch
(2 score points) at 48 hr. In 2 of these 5 patients, the
increase in vesicles was accompanied by an increase in
itch of 0 score points at baseline to 2 points at 48 hr. Three
of these 5 patients showed 2 score points for itch both
at baseline and at 48 hr. In these 3 patients, the absence
of an increase in itch may be explained by the fact that
they already showed significant itch at baseline. More-
over, in 2 of these 3 patients, the increase in vesicles was
not accompanied by an increase in affected area score
points, which may explain the absence of an increase
in itch.
Table 3 provides an overview of the number of patients
whoshowedan increase inhandeczemaafterHDMprovo-
cation versus placebo provocation, and the numbers of
skin responders, vesicle responders, anderythemarespon-
ders. Of the DASI sub-scores, we present only the respon-
ders to the objective items erythema and vesicles, because
the other items showed no significant increase in eczema
as compared with baseline at the different time points.
There were significant differences between the number of
patients who showed an increase in eczema after HDM
provocation and the number of patients who showed an
increase after placebo provocation at 1 hr (p = 0.001),
6 hr (p = 0.002), and 24 hr (p = 0.04). Overall, there
were more vesicle responders than erythema responders.
Association between bronchial reactions and hand
eczema
Table 4 provides an overview of the bronchial reactions
and skin response at 48 hr. In 9 of the 18 patients, the
maximum dose of HDM could not be given, because of an
early fall in FEV1, varying from 16% to 35%. In total, 6
of the 18 patients had a history of asthma, and in these
6 patients the highest HDM concentration could not be
given. Twelve patients showed an EAR, and 5 patients
showed a LAR.
At 48 hr, there were 10 patients who showed an
increase in eczema after HDM provocation, and in 7
of these 10 patients the increase in hand eczema was
preceded by an EAR. In 4 of the 10 HDM responders,
concomitant EARs and LARs were observed.
Twelve patients showed an EAR. At 48 hr, 6 of these
12 patients were skin responders and 6 patients were
not. The differencewas not significant (p = 0.64). There
were also no significant differences at 6 and 24 hr, and no
significant differences in patients with an EAR and vesicle
responders or erythema responders.
Logistic regression analysis showed no significant
correlation betweenmaximum FEV1 placebo-corrected
early and skin responders, vesicle responders and
erythema responders at 6, 24 and 48 hr.
Five patients showed a LAR. At 48 hr, there were no
significant differences in the number of patientswhowere
skin responders or not (p = 0.12). There were also no
significant differences at 6 and24 hr. Therewere 4 vesicle
responders at 48 hr; 3 of the 4 showed an LAR, and 1 of
© 2012 John Wiley & Sons A/S
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the 4 did not. The difference was significant (p = 0.04).
At 24 hr, there were also 4 vesicle responders; 3 of the 4
showed an LAR, and 1 of the 4 did not. The differencewas
significant (p = 0.04). At 6 hr, therewere no significant
differences. There were no significant differences in those
with an LAR and those who were erythema responders
or not at the different time points.
Logistic regression analysis showed no correlation
between maximum FEV1 placebo-corrected late and
skin responders at 48 hr.
Serum IgE levels and eosinophils
Patient 2 was included in the study because of a positive
prick test reaction to HDM (inclusion criterion), but
specific HDM IgE was not elevated.
Table 3 shows the mean levels of total IgE and HDM-
specific IgE in skin responders and non-skin responders
at the different time points when hand eczema was eval-
uated. The mean total IgE level was significantly higher
in skin responders than in non-skin responders at 24 hr
(p = 0.03). The mean total IgE level in skin respon-
ders at 6 and 48 hr was higher than that in non-skin
responders at these time points, but not significantly dif-
ferent. The mean total IgE level was significantly higher
in vesicle responders than in non-vesicle responders at
24 hr (p = 0.02).
The mean (SD) serum eosinophil level 24 hr after
HDM challenge, 0.54 × 109/l (0.32), was significantly
different from baseline: 0.41 × 109/l (0.22) (p = 0.04).
After placebo challenge, there was no significant
difference from baseline at 24 hr. The serum eosinophil
levelafterHDMprovocationandeosinophils (eosinophils
at24 hr – eosonophilsatbaseline)afterHDMprovocation
were not significantly different between skin responders
and non-skin responders at different time points. Thiswas
the same for vesicle responders.
Discussion
Our results showed that there was significantly more
often an increase in hand eczema after HDM provocation
Table 3. Number of responders and mean [± standard deviation (SD)] serum IgE levels at different time points
Assessments 1 hr 6 hr 24 hr 48 hr







Placebo responders n 1 1 2 5
Skin responders n 2 4 6 8
Total IgE 748 (987) 1927 (2137) 2106 (2439)
#p = 0.03
1605 (2260)
HDM-specific IgE 3 (3) 51 (56) 38 (48) 32 (43)
Non-skin responders n 16 14 12 10
Total IgE 985 (1695) 682 (1404) 385 (484) 442 (515)
HDM-specific IgE 33 (40) 23 (33) 26 (35) 28 (38)
Vesicle responders n 0 1 4 4
Total IgE − 1213 2517 (2868)
#p = 0.02
1289 (2472)
HDM-specific IgE − 100 54 (54) 30 (47)
Non-vesicle responders n 18 17 14 14
Total IgE 959 (1612) 944 (1660) 514 (734) 864 (1393)
HDM-specific IgE 30 (39) 26 (36) 23 (33) 29 (38)
Erythema responders n 1 2 1 3
Total IgE 1446 1330 (165) 5000 1710 (2850)
HDM-specific IgE 4 52 (68) 100 40 (53)
Non-erythema responders n 17 16 17 15
Total IgE 930 (1656) 912 (1709) 721(1296) 809 (1360)
HDM-specific IgE 31 (40) 27 (37) 26 (36) 27 (38)
HDM, house dust mite; n, number of participants.
Total IgE and HDM-specific IgE are represented as mean kU/l (± SD). p-values are shown only for significant differences.
∗p-values represent significant differences in the number of responders after HDM challenge and after placebo challenge.
#p-values represent significant differences in the mean total IgE level per group responders and non-responders.
Skin responders: DASI after HDM > 0 and DASI after HDM > DASI after placebo.
Vesicle responders: vesicles after HDM > 0 and vesicles after HDM > vesicles after placebo.
Erythema responders: erythema after HDM > 0 and erythema after HDM > erythema after placebo.
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Table 4. Highest house dust mite (HDM) concentration, maximum FEV1 and FEV1 placebo-corrected early and late, DASI, vesicles,
and erythema after HDM and placebo provocation at 48 hr











P-C HDM Placebo HDM Placebo HDM Placebo
1 10 000 + 1 + 4 − 1 + 2 0 0 0 0 0 0
2 10 000 − 2 0 + 1 + 8 4 0 2 0 2 0
3 10 000 − 14 − 17 + 2 − 1 1 0 0 0 0 0
4 10 000 − 23 − 24 − 14 − 16 1 − 2 1 0 − 1 0
5 10 000 − 20 − 22 − 4 − 8 0 − 1 0 0 0 0
6 80 − 19 − 15 − 21 − 18 8 − 3 3 0 0 − 2
7 2000 − 31 − 29 − 20 − 18 3 0 0 0 1 0
8 10 000 − 27 − 26 − 11 − 10 1 0 0 0 1 0
9 10 000 − 5 − 3 − 3 0 0 3 − 1 1 0 0
10 10 000 − 11 − 7 − 3 + 2 8 0 0 0 0 0
11 10 000 − 18 − 16 − 12 − 6 3 4 1 3 0 − 2
12 2000 − 18 − 20 − 3 − 2 0 1 0 0 0 0
13 400 − 18 − 18 + 1 + 2 0 0 0 0 0 0
14 400 − 16 − 13 − 11 − 9 1 2 1 2 0 0
15 400 − 31 − 30 − 8 − 7 0 0 0 0 0 0
16 400 − 22 − 20 − 4 − 3 0 0 0 0 0 0
17 2000 − 35 − 32 − 30 − 29 4 2 2 1 0 0
18 400 − 20 − 14 − 23 − 23 0 0 0 0 0 0
DASI, Dyshidrotic Eczema Area and Severity Index; FEV1, forced expiratory volume in 1 second; FEV1 placebo-corrected (%
baseline) = maximum FEV1 HDM (% baseline) – corresponding FEV1 placebo (% baseline); P, placebo; P-C, placebo-corrected; FEV1,
maximum percentage change from baseline FEV1.
FEV1 P-C presented in bold: early and late asthmatic reactions.
than after placebo provocation.We demonstrated that an
increase of vesicles was preceded by a LAR. Patients with
an increase of the DASI had as a group a higher mean
total IgE level.
From this, we conclude that HDM provocation espe-
cially induced the formation of vesicles. The clinical
manifestation of a mild flare of vesicular hand eczema
often begins with the formation of vesicles without
inflammation or with slight inflammation. These clinical
findings in vesicular hand eczema support the occurrence
of mild flares after HDM provocation in our study. We
also observed an early increase in erythema, which may
represent vasodilatation as an early sign of inflammation.
The EAR is the result of airflow obstruction that occurs
shortly after the allergen challenge by degranulation
of mast cells, is maximal at 10 and 20 min or slightly
longer, and resolves spontaneously by 2–3 hr. The LAR
is an episode of airway obstruction that appears following
spontaneous resolutionof theEAR. In theLAR, inflamma-
tory cells play an essential role, appearing approximately
4–5 hr after allergen challenge, and possibly persisting
for ≥ 12 hr. We hypothesized that bronchial inflamma-
tion afterHDM inhalation leads to a high concentration of
inflammatory mediators being released into the circula-
tion by the bronchus-associated immune system, which
may subsequently lead to increasedhandeczema. Inhand
eczema patients who were allergic to HDM, we observed
that the development of vesicleswas preceded by the LAR,
which may also support our hypothesis. The association
with the LAR is plausible, because the LAR is based on
extensive bronchial inflammation (13, 14).
Although it was not a part of this study, it was note-
worthy that 5 of 8 patients who started with the HDM
provocation reported, at the second placebo provocation,
that they had noticed an increase of eczema 4–5 days
after the first HDM provocation. Four of these 5 patients
had current eczema and reported more hand eczema and
atopic eczema after HDM provocation, and 1 of these 5
only reported more hand eczema 4–5 days after HDM
provocation. These findings indicate that the inflamma-
tory skin response probably occurred late after allergen
challenge, and that the follow-up should be extended.
However, a difficulty in having a longer observation
period is that confounders may affect the outcome.
We are not aware of any other study on inhalation
HDM inhalation challenges in hand eczema. Brinkman
et al. (8)studiedallergeninhalationchallenge in16atopic
dermatitis patients, 8with and8without allergic asthma,
and showed a flare-up of skin lesions in both groups, and a
significantlyhigher increase intheatopicdermatitisgroup
with concomitant allergic asthma. They showed a signifi-
cant correlationbetween thepercentageof late fall in peak
expiratory flow (3–8 hr after challenge) and the increase
in atopic dermatitis. This seems to support the association
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that we found between the LAR and the increase in the
number of vesicles in hand eczema in this study.
We expected that, in the sample size calculation, the
DASI would increase by 28 points at 48 hr after HDM
provocation and that there would be no increase after
placebo provocation. Our results showed an increase in
the DASI of up to a maximum of only 8 points after HDM
provocation in 10 patients. This was clearly less than we
had expected. It is possible that we could have observed
a greater increase in eczema after HDM provocation if
we had used a longer post-challenge observation period.
However, desquamation is an item in the DASI score that
cannot contribute to the initial increase (i.e. 48 hr) when
there is a mild flare. The affected area score was based
on the mean percentage of affected skin, with 1 point
for each 20% of affected area. In this study with only
minor changes in eczema, this item was not expected to
increase. At the time when we started this study, the
DASI seemed to be most suitable in the absence of other
validated instruments. Weistenhofer et al. (15) recently
reported that, for quantifying mild skin changes, a score
measured with a more differentiated scale was needed
to register minimal lesions. We conclude that the DASI
probably does not meet these criteria.
The degree of association between vesicular hand
eczema and atopy is unclear. No associationwas reported
in one study (2), whereas in another it was reported that
atopy was a predisposing factor in the pathogenesis of
vesicular hand eczema (1). We noticed that 77% of the
patients with vesicular hand eczema who wanted to par-
ticipate did not showapositive prick test reaction toHDM.
We conducted the study in patients with vesicular hand
eczema who were atopic and allergic to HDM. This group
may constitute a minority among vesicular hand eczema
patients.Moreover,many eligible patientswere unwilling
to participate. We had not anticipated this, and it was a
reason why inclusion took so long.
Some limitations in the design of the study have
to be mentioned. One limitation was the use of anti-
inflammatory inhalation medication during the study
period. Inhaled corticosteroids have systemic effects
on the concentrations of circulating pro-inflammatory
cytokines (16), and may interfere with the development
of skin symptoms after HDM provocation. Participants
with an LAR were treated with inhaled corticosteroids,
owing to a fall in FEV1 after HDM provocation, and
this may have been a confounder. During the study, the
patients had to continue using topical steroids or other
anti-inflammatory topical medication at the same fre-
quency and strength during the provocation, and this
may have had an effect on the outcome. One patient
reported an exacerbation of hand eczema, which had
started some days before the start of the placebo provo-
cation. However, she did not use clobetasol, which she
normally used. Thus, the increase in her DASI score as
compared with baseline after placebo provocation was
unreliable. However, if she had continued using clobeta-
sol, which is a very potent corticosteroid, it would have
been a confounder.
In this study, other variables, such as allergens
other than HDM allergen, could have been confounders.
Although not all patients were fully screened for allergies,
there were subjects with multiple sensitizations in this
study. However, in most of those cases, HDM was the
strongest sensitizer. In addition, exposure to HDM in this
study was probably greater than the natural exposure to
allergens. In 11 of 18 patients, patch testswere performed
to exclude clinically relevant contact allergies.
In an outpatient setting, compliance with topical
treatment is difficult to control. The question is whether
patients should have been tested at the time of an
exacerbation. It would be probably better to treat the
hand eczema for disease control before starting with
provocations.
Our test method is not completely comparable with
the role of exposure to HDM allergen inhalation as it
naturally occurs. In a domestic situation, HDM allergen
is probably inhaled at low concentrations for prolonged
periods of time. Although our study design was double-
blind, the patients who experienced a decrease in FEV1 or
symptoms of dyspnoea could guess that they had inhaled
HDM allergen. These patients could have reported more
pruritus, which could influence the subjective item itch
in the DASI score. However, we did not find a significant
increase in itch after HDM challenge.
In conclusion, the results showed that hand eczema
increased significantly more after HDM provocation than
after placebo provocation. House dust mite inhalation
challenges increased especially vesicles, which was pre-
ceded by a LAR. The group patients with an increase
of hand eczema tended to have a higher mean total IgE
level. These findings may contribute to a better aetiologi-
cal classification of chronic hand eczema, and may have
implications for the prevention of flares in a sub-group of
hand eczema patients.
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